OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
The taxotere burn is not the hottest, latest dance sweeping the country, it is a little discussed complication that can strike a man while having chemotherapy for the treatment of prostate cancer. If the infusion equipment is not secured tightly or the vein not properly accessed and any of the taxotere is allowed to leak [...]
Besides the blood problems and the gastric problems I discussed in the last two posts, taxotere can also cause hair loss and have effects on your skin and nails. The q3wk dose of taxotere (higher dose once every 3 weeks) is associated with reversible hair loss in two-thirds of men going on that schedule and [...]
Taxotere can cause severe irritation of the liver, so your liver functions must be monitored via regular blood tests. If the blood screens show you are developing liver problems a modification of your dosing or possibly stopping further infusions is warranted. Liver damage caused by taxotere is usually reversible when the drug is stopped, however [...]